Di Ma

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 5

Top Topics

Tyrosine Kinase

Small Cell Lung Cancer

Brain Metastases

Patient Reported

Top Venues

Thoracic cancer

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Yan Li, Ziyi Xu, Shou-Zheng Wang, Yi-Xiang Zhu, Di Ma, Yuxin Mu, Jian-Ming Ying, Jun-Ling Li, Pu-Yuan Xing
Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA. Thoracic cancer 13 (15) (2022)
Di Ma, Yan Zhang, Puyuan Xing, Xuezhi Hao, Mengzhao Wang, Yan Wang, Li Shan, Tao Xin, Hongge Liang, Yang Du, Zhaohui Zhang, Li Liang, Jun-Ling Li
Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib. Thoracic cancer 10 (5) (2019)
Hai-Yan Xu, Guangjian Yang, Lu Yang, Yaning Yang, Di Ma, Junling Li, Xuezhi Hao, Puyuan Xing, Yan Wang
Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance. Thoracic cancer 10 (5) (2019)
Shouzheng Wang, Puyuan Xing, Ke Yang, Xuezhi Hao, Di Ma, Yuxin Mu, Jun-Ling Li
Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations. Thoracic cancer 10 (6) (2019)
Guangjian Yang, Di Ma, Haiyan Xu, Lu Yang, Junling Li, Puyuan Xing, Xuezhi Hao, Yan Wang
Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world study. Cancer medicine 8 (13) (2019)